Dark

RIGL
Rigel Pharmaceuticals Inc. (New)
stock NASDAQ

At Close

May 9, 2025 3:59:57 PM EDT

18.77USD-0.688%(-0.13)250,170

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 9, 2025 8:54:30 AM EDT

18.00USD-4.761%(-0.90)400

After-hours

May 8, 2025 4:42:30 PM EDT

18.80USD-0.371%(-0.07)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

09:43AM EST Rigel Pharmaceuticals Granted U.S. Patent #11,230,554 'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds' Benzinga

Jan 10, 2022

04:16PM EST Rigel to Present at the J.P. Morgan Healthcare Conference PR Newswire

08:53AM EST Rigel Pharmaceuticals Sees Sees Net Product Sales Of $17.6M For Q4, Compared To $17.7M YoY Benzinga

08:44AM EST Rigel Pharma Expects To Report Total Revenue Of Approximately $20.4 Mln In Q4 RTTNews

08:40AM EST Rigel Pharmaceuticals Provides Business Update PR Newswire

Jan 7, 2022

08:04PM EST Rigel Pharmaceuticals Announces Inducement Grants RTTNews

07:01PM EST Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing PR Newswire

Dec 21, 2021

08:56AM EST Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday that its collaboration partner, Kissei Pharmaceutical Co., Ltd., has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP). RTTNews

08:33AM EST Rigel: Fostamatinib Meets Primary Endpoint In Phase 3 Trial In Japan For Chronic Immune Thrombocytopenia RTTNews

08:31AM EST Rigel Announces Fostamatinib Met Primary Endpoint In Phase 3 Trial In Japan For Treatment Of Chronic Immune Thrombocytopenia Benzinga

08:31AM EST Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of PR Newswire

Dec 16, 2021

09:05AM EST Rigel Appoints Kamil Ali-Jackson To Board RTTNews

09:02AM EST Rigel Appoints Kamil Ali-Jackson to Board of Directors PR Newswire

Dec 14, 2021

09:15AM EST Rigel Pharmaceuticals Granted U.S. Patent #11,198,689 ' Compositions and methods for inhibition of the JAK pathway' Benzinga

Nov 15, 2021

08:51AM EST Rigel Pharmaceuticals, Inc. (RIGL) announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts. The company will reduce its workforce by 16%, resulting in the elimination of 31 positions, primarily in the research organization. RTTNews

08:34AM EST Rigel Pharma Plans To Exit Early-stage Research And Focus Resources On Development Programs And Its Commercial Efforts RTTNews

08:31AM EST Rigel Sharpens Focus on Its Advanced Portfolio Opportunities PR Newswire

Nov 9, 2021

07:31AM EST Rigel to Participate in Two Upcoming Investor Conferences PR Newswire

Nov 3, 2021

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

Nov 2, 2021

04:53PM EDT Rigel Pharmaceuticals Q3 EPS $(0.12) Misses $(0.10) Estimate, Sales $21.54M Miss $23.56M Estimate Benzinga

04:13PM EDT Rigel Pharma Q3 Loss/share $0.12 Vs. Loss $0.08 Year Ago RTTNews

04:02PM EDT Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update PR Newswire

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 26, 2021

07:31AM EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 PR Newswire

Oct 8, 2021

04:50PM EDT Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing PR Newswire

Sep 2, 2021

07:31AM EDT Rigel to Participate in Three Upcoming Investor Conferences PR Newswire

Sep 1, 2021

08:56AM EDT Rigel Pharmaceuticals Inc. (RIGL) said that data from NIH/NHLBI-Sponsored phase 2 trial of fostamatinib in hospitalized COVID-19 patients were published in clinical infectious diseases, an official publication of the Infectious Disease Society of America. RTTNews

07:37AM EDT Rigel Pharma : Phase 2 Trial Data Show Fostamatinib Improves Clinical Outcomes In Hospitalized COVID-19 Patients RTTNews

07:31AM EDT Data from NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In Hospitalized COVID-19 Patients Published In Clinical Infectious Diseases Benzinga

07:31AM EDT Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized PR Newswire

Aug 31, 2021

09:52AM EDT Rigel Pharmaceuticals Granted U.S. Patent Titled 'ACVR2A-specific antibody and method of treatment of muscle atrophy' Benzinga

Aug 13, 2021

07:54AM EDT Rigel Pharmaceuticals Inc. (RIGL) said Friday that the U.S. Food and Drug Administration did not issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults, due to insufficient clinical data. RTTNews

07:34AM EDT Rigel Pharmaceuticals Says FDA Informed Co. that Clinical Data Submitted In Late May From Phase 2 Trial Of Fostamatinib In COVID-19 Patients Are Insufficient For Emergency Use Authorization At This Time Benzinga

07:34AM EDT Rigel : FDA Declines To Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults; Stock Down RTTNews

07:31AM EDT Rigel Pharmaceuticals Provides Update on COVID-19 Program PR Newswire

Aug 3, 2021

04:31PM EDT Rigel Pharmaceuticals Q2 EPS $(0.08) Beats $(0.11) Estimate, Sales $26.27M Beat $20.37M Estimate Benzinga

04:06PM EDT Rigel Pharma Q2 Loss/share $0.08 Vs. Loss $0.10 Year Ago RTTNews

04:02PM EDT Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 14, 2021

07:32AM EDT Rigel Pharma Presents New TAVALISSE Data Analyses At ISTH 2021 Congress RTTNews

07:31AM EDT Rigel Pharmaceuticals To Present Data From Its TAVALISSE Program At International Society On Thrombosis And Haemostasis Virtual Congress Ju. 17-21 Benzinga

07:31AM EDT New TAVALISSE(r) Data Analyses To Be Presented at International Society on PR Newswire

Jun 29, 2021

02:50PM EDT Rigel's Fostamatinib Selected for NIH ACTIV-4 COVID-19 Trial Benzinga

07:55AM EDT Rigel Pharmaceuticals Inc. (RIGL) said that its novel oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, has been selected for a National Institutes of Health or NIH ACTIV-4 or Accelerating COVID-19 Therapeutic Interventions and Vaccines trial in hospitalized patients with COVID-19. RTTNews

07:35AM EDT Rigel Pharma Says Fostamatinib Selected For NIH ACTIV-4 COVID-19 Clinical Trial RTTNews

07:34AM EDT Rigel Pharmaceuticals Announces Fostamatinib, The Company's Novel Oral Spleen Tyrosine Kinase Inhibitor, Selected for NIH ACTIV-4 COVID-19 Clinical Trial Benzinga

07:31AM EDT Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial PR Newswire

May 27, 2021

07:39AM EDT Clinicaltrials.gov Site Shows Rigel Pharmaceuticals Recruiting For Observational Study Of Fostamatinib Benzinga

May 26, 2021

07:31AM EDT Rigel to Present at the Jefferies Virtual Healthcare Conference PR Newswire

May 14, 2021

07:31AM EDT Rigel Pharmaceuticals Appoints Alison Hannah To Its Board RTTNews

07:31AM EDT Rigel Appoints Alison L. Hannah, M.D. to Board of Directors PR Newswire

May 13, 2021

11:33AM EDT Rigel Therapeutics Files For U.S. Patent Titled 'HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS' Benzinga

May 12, 2021

01:26PM EDT UPDATE: Cantor Believes Data From Curis On Its IRAK1 Inhibitor Program Validates Rigel Pharma's Inhibitor Target, Says '...should be positive readthrough to RIGL's IRAK1/4 program, which is moving along...' Benzinga

May 10, 2021

10:08AM EDT Cramer Advises Viewers On American Airlines, Luminar Technologies And More Benzinga

May 5, 2021

04:32PM EDT Rigel Pharmaceuticals Q1 EPS $0.22 Up From $0.13 YoY, Sales $81.02M Beat $31.05M Estimate Benzinga

04:11PM EDT Rigel Pharmaceuticals Inc. (RIGL) revealed a profit for its first quarter that rose from the same period last year. RTTNews

04:06PM EDT Rigel Reports Q1 EPS Of $0.22 Vs. $0.13 Last Year RTTNews

04:02PM EDT Rigel Reports First Quarter 2021 Financial Results and Provides Business Update PR Newswire

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 28, 2021

07:31AM EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2021 PR Newswire

Apr 13, 2021

10:01AM EDT Rigel Pharmaceuticals Granted U.S. Patent Titled 'RIP1 inhibitory compounds and methods for making and using the same' Benzinga

07:19AM EDT Biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19. RTTNews

07:04AM EDT Rigel Pharmaceuticals Phase 2 Clinical Trial Of Fostamatinib In Hospitalized Patients with COVID-19 Met Primary Endpoint Benzinga

07:02AM EDT Rigel Reports Positive Topline Results From Phase 2 Clinical Trial To Evaluate Safety Of Fostamatinib RTTNews

07:02AM EDT Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in PR Newswire

Apr 7, 2021

07:32AM EDT Rigel Announces Closing Of Strategic Collaboration With Lilly; Says Agreement Is Effective As Of Mar. 27, Rigel Has Received $125M Upfront Payment Benzinga

07:31AM EDT Rigel Announces Closing Of License Agreement With Lilly RTTNews

07:31AM EDT Rigel Announces Closing of Strategic Collaboration with Lilly PR Newswire

Mar 11, 2021

07:45AM EST Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company's oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60. RTTNews

07:37AM EST Rigel Completes Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In COVID-19 Patients RTTNews

07:37AM EST Rigel Announces Completion Of Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In Hospitalized COVID-19 Patients Benzinga

07:31AM EST Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase PR Newswire

Mar 9, 2021

05:20AM EST Rigel Pharmaceuticals Awarded U.S. Patent 10,941,134 'AMPK-activating heterocyclic compounds and methods for using the same' Benzinga

05:18AM EST Rigel Pharmaceuticals Awarded U.S. Patent 10,941,135 'Nrf2 activating compounds and uses thereof' Benzinga

05:16AM EST Rigel Pharmaceuticals Awarded U.S. Patent 10,941,140 'IRAK inhibitors and method for making and using' Benzinga

Mar 2, 2021

04:03PM EST Rigel Pharmaceuticals Q4 Loss/share $0.11 Vs. Loss $0.10 Year Ago RTTNews

04:03PM EST Rigel Pharmaceuticals Q4 EPS $(0.11), Inline, Sales $18.50M Beat $18.10M Estimate Benzinga

04:01PM EST Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides PR Newswire

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 23, 2021

07:31AM EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year PR Newswire

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

12:09PM EST HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $11 Benzinga

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

06:53AM EST Eli Lilly and Co. (LLY) and Rigel Pharmaceuticals Inc. (RIGL) said that they have collaborated to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases. RTTNews

06:37AM EST Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases; Lilly Will Pay An Upfront Cash Payment To Rigel Of $125M Benzinga

06:35AM EST Lilly, Rigel Announce Global License Agreement To Co-develop Rigel's R552 In All Indications RTTNews

06:30AM EST Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for PR Newswire

Jan 29, 2021

02:56PM EST Rigel Pharmaceuticals Issues Release Reiterating Earlier Report Of Co Winning $16.5M Contract From Department Of Defense Benzinga

02:52PM EST Rigel Gets $16.5 Mln From U.S. Department Of Defense For Phase 3 Clinical Trial Of Fostamatinib In COVID-19 Patients RTTNews

02:46PM EST Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 PR Newswire

11:47AM EST Rigel Pharmaceuticals Awarded $16.5M Contract To Support Phase III Clinical Trial Using Fostamatinib Against COVID-18 Benzinga

Jan 11, 2021

07:55AM EST Rigel Pharmaceuticals, Inc. (RIGL) on Monday provided a business update, including preliminary total revenue and TAVALISSE (fostamatinib disodium hexahydrate) bottles sold for the fourth quarter, Fast Track designation granted for warm autoimmune hemolytic anemia (wAIHA), and the company's COVID-19 program. RTTNews

07:43AM EST Rigel Expects To Report Q4 Sales Of $18.4M Benzinga

07:34AM EST Rigel Pharma Reports 2020 TAVALISSE Preliminary Net Product Sales Of About $61.7 Mln RTTNews

07:34AM EST Rigel Expects To Report Q4 Sales Of $18.4 M Benzinga

07:31AM EST Rigel Pharmaceuticals Provides Business Update PR Newswire

Jan 7, 2021

07:31AM EST Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire

Dec 4, 2020

07:33AM EST Rigel Pharma Highlights 2 Poster Presentations Will Be Presented At American Society Of Hematology Dec. 5-8 Benzinga

07:30AM EST Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual PR Newswire

Nov 23, 2020

07:32AM EST Rigel and Medison Announce Health Canada Approval of TAVALISSE, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia Benzinga

07:31AM EST Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia PR Newswire

Nov 17, 2020

07:51AM EST Rigel Reaches Agreement With FDA On Study Design Of Phase RTTNews

07:37AM EST Rigel Pharma Reaches Agreement With FDA On Final Design Of FORWARD Study RTTNews

07:32AM EST Rigel Pharma Reports Finalization Of Study Design Of Its Ongoing Phase 3 Trial Of Fostamatinib In Warm Autoimmune Hemolytic Anemia Benzinga

07:31AM EST Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of PR Newswire

Nov 10, 2020

07:31AM EST Rigel to Present at the Jefferies Virtual London Healthcare Conference PR Newswire

Nov 9, 2020

09:38AM EST Benzinga's Top Upgrades, Downgrades For November 9, 2020 Benzinga

06:08AM EST A Peek Into The Markets: US Stock Futures Jump Following Joe Biden's Victory Benzinga

05:10AM EST JP Morgan Downgrades Rigel Pharmaceuticals to Neutral Benzinga

Nov 5, 2020

04:22PM EST Rigel Pharmaceuticals Q3 EPS $(0.08) Down From $(0.07) YoY, Sales $18.39M Up From $9.14M YoY Benzinga

04:05PM EST Rigel Pharma Q3 Loss/share $0.08 Vs. Loss $0.07 Year Ago RTTNews

04:03PM EST Rigel Pharmaceuticals Q3 EPS $(0.08) Down From $(0.07) YoY, Total Sales $18.39M Vs $20.875M YoY Benzinga

04:02PM EST Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

07:31AM EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 PR Newswire

Oct 9, 2020

07:54AM EDT Rigel Pharmaceuticals Inc. (RIGL) announced enrollment of the first patients in a multicenter, phase 2 trial that will evaluate the safety of fostamatinib for the potential treatment of hospitalized COVID-19 patients. fostamatinib is the company's oral spleen tyrosine kinase inhibitor. RTTNews

07:34AM EDT Rigel Pharma Announces Enrollment Of First Patients In Phase 2 Trial Of Fostamatinib For COVID-19 Patients RTTNews

07:30AM EDT Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova Benzinga

07:30AM EDT Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova PR Newswire

Sep 17, 2020

09:46AM EDT Return On Capital Employed Overview: Rigel Pharmaceuticals Benzinga

07:52AM EDT Rigel Pharmaceuticals, Inc. (RIGL) said Thursday that a multicenter, Phase 2 trial has started to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. RTTNews

07:34AM EDT Rigel Pharma Begins Phase 2 Trial To Evaluate Safety Of Fostamatinib For Hospitalized COVID-19 Patients RTTNews

07:31AM EDT Rigel Announces NIH/NHLBI-Sponsored Trial Of Fostamatinib In Hospitalized COVID-19 Patients In Collaboration With Inova Benzinga

07:31AM EDT Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized PR Newswire

Sep 9, 2020

07:31AM EDT Rigel to Present at Two Upcoming Investor Conferences PR Newswire

Sep 2, 2020

07:31AM EDT Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference PR Newswire

Aug 21, 2020

07:35AM EDT Rigel Pharma Announces Inducement Grants Under NASDAQ Listing Rule RTTNews

07:30AM EDT Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing PR Newswire

Aug 6, 2020

07:39AM EDT Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $8 Benzinga

Aug 5, 2020

11:48AM EDT Looking Into Rigel Pharmaceuticals's Return On Capital Employed Benzinga

Aug 4, 2020

04:16PM EDT Rigel Q2 Net Loss $17.6 Mln Or $0.10/Shr Vs Net Loss $20.6 Mln Or $0.12/Shr Last Year RTTNews

04:08PM EDT Rigel Pharmaceuticals Q2 EPS $(0.10) Beats $(0.13) Estimate, Sales $16.02M Beat $13.75M Estimate Benzinga

04:02PM EDT Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, PR Newswire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 28, 2020

07:31AM EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 PR Newswire

Jul 27, 2020

04:04PM EDT Why Rigel Pharmaceuticals Is Moving Today Benzinga

12:59PM EDT Rigel Pharmaceuticals shares are trading higher after the company announced the publication of post-hoc data analysis of TAVALISSE in the British Journal of Haematology. Benzinga

07:35AM EDT Rigel Announces Post-hoc Data Analysis Of TAVALISSE In Adult Patients With Immune Thrombocytopenia Published In The British Journal Of Haematology Benzinga

07:33AM EDT Rigel Says Post-hoc Data Analysis Of TAVALISSE In Adult Patients With Immune Thrombocytopenia Published RTTNews

07:30AM EDT Rigel Announces Post-hoc Data Analysis of TAVALISSE(r) in Adult Patients with PR Newswire

Jul 15, 2020

09:47AM EDT Morning Market Stats in 5 Minutes Benzinga

04:49AM EDT 55 Biggest Movers From Yesterday Benzinga

Jul 14, 2020

02:41PM EDT Mid-Afternoon Market Update: Dow Climbs 400 Points; nCino Shares Jump Benzinga

12:11PM EDT Mid-Day Market Update: Dow Rises 1%; Rigel Pharmaceuticals Shares Spike Higher Benzinga

11:31AM EDT Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views Benzinga

10:06AM EDT Morning Market Stats in 5 Minutes Benzinga

10:00AM EDT Shares of Rigel Pharmaceuticals, Inc. (RIGL) jumped more than 80% jump on the news that an investigator-sponsored trial (IST) has been started by Imperial College London to study its approved treatment fostamatinib, in patients with Covid-19 pneumonia. RTTNews

08:11AM EDT Rigel Pharmaceuticals Inc. (RIGL) announced the initiation of an investigator-sponsored trial or IST being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase or SYK inhibitor, for the treatment of COVID-19 pneumonia. RTTNews

08:11AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tues., Jul. 14, 2020: KBE, NFLX, RIGL, JNJ, CIDM Benzinga

07:32AM EDT Rigel Announces Initiation Of Investigator-Sponsored Trial Of Fostamatinib In Patients With COVID-19 Pneumonia RTTNews

07:31AM EDT Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with PR Newswire

07:30AM EDT Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia Benzinga

05:11AM EDT 80 Biggest Movers From Yesterday Benzinga

Jul 13, 2020

08:34AM EDT Rigel Pharmaceuticals Shares On Watch Premarket As Traders Circulate Study Titled 'A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic' Benzinga

08:30AM EDT Rigel Pharmaceuticals Shares Premarket As Traders Circulate Study Titled 'A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic' Benzinga